Uscom Limited · ASX:UCM
Uscom — Investor Presentation (November 2021)
24 slides from Uscom's investor presentation, Nov 24, 2021
Slide 1: Uscom - New Growth
PRESENTATION AND UPDATE Uscom - New Growth ASX: UCM Prof. Rob Phillips Chairman and CEO, Uscom Limited November 24, 2021
Slide 2: Summary
Summary NEW GROWTH SUMMARY “The choice is simple: continue growing at 24% PA, or invest in new growth at an inflection point in the company’s history” Prof. Rob Phillips 2 | Strong Growth and investment for Future
Slide 3: Uscom Vision
Uscom Vision Our Vision “ Building a world leading medical technology enterprise combining lifesaving cardiovascular and pulmonary technologies that establish new standards of medical excellence and global academic recognition, with sustainable profits. ” Prof. Rob Phillips 3 | Motivated by Vision,
Slide 4: Uscom Overview
Uscom Overview ASX Listed Global Vision and Global cardiovascular and pulmonary medical technology Ambitions Sydney, Singapore, Beijing, Budapest, Visionary and innovative Auckland, London, LA. corporate culture Actively pursuing growth and scale Patented Apex Profit and Cash Flow Technologies World
Slide 5: Uscom Snapshot
Uscom Snapshot Uscom is an established medical technology enterprise preparing for a growth inflection with a global footprint and an expanding international network of operations acting as hubs for new distributors 7 Global centres Expanding distribution hubs AUD$ 5.6m annual receipts (FY21) 2 Manu
Slide 6: Growth Markets
Growth Markets High value technologies in large markets with strong predicted growth Applications Critical care, Clinics, CRO, Pharma and “Hospital in home” Subjects Neonates, children, adults and the elderly Condition responsible for 75% of global mortality Heart failure, sepsis, hypertension, vasc
Slide 7: FY21 Results
FY21 Results $6.00 Continued Growth 5.58 $5.00 Sales, revenue and cash receipts 4.55 4.6 4.28 growth, and first ever positive annual $4.00 3.86 operating cash flow. 3.48 First year of cash receipts greater than $3.00 $5.5m despite being a difficult trading year beset by intermittent lockdowns $m AUD
Slide 8: Sustained Growth
Sustained Growth $0.86m $2.94m $5.58m FY2012 UCM FY2016 UCM FY2021 UCM Total cash receipts Total cash receipts Total cash receipts • Total cash receipts $5.58m, up 21% from $4.60m • First ever cash receipts $6.00 >$5.5m $5.00 • 9 year total cash receipts trend growth $4.00 535% total increase $m A
Slide 9: eHealth Technology
eHealth Technology Frontiers in Digital Health technology USCOM 1A data data USCOM 1A software SpiroReporter Uscom Advanced Haemodynamic APP SpiroSonic APP Blue Sky Uscom eHealth Ecosystem data data Revenue Cascade AI, Meta Data, BP+ Reporter Licensing, Cloud services, Pay per use, VENTITEST-S Renta
Slide 10: eHealth Growth
eHealth Growth eHealth Market forecast to grow at CAGR of 19.4% $250.00 Blue Sky USD 206.3 Billion Uscom eHealth Ecosystem $200.00 USD $Billion eHealth is a health delivery revolution $150.00 Uscom is committed to eHealth $100.00 BlueSky eHealth expected to underwrite Uscom USD 59.5 Billion gr
Slide 11: COVID and Uscom
COVID and Uscom COVID – USCOM 1A • COVID - Lung virus which attacks cardiovascular system • Patients mostly die from cardiovascular failure • USCOM 1A best device for rapid CV monitoring and therapy • USCOM 1 – recommended by China NHMC for severe COVID treatment • >50 new China infectious disease c
Slide 12: SpiroSonic AIR
SpiroSonic AIR “Hospital in Home” – Asthma, COVID, COPD and OLD The SpiroSonic AIR Cycle – a wireless connection of data, information, diagnosis and reports generating a cascade of revenue eHealth Revenue Cascade • Device sale • APP Sale • Software sale • Cloud storage - Big data • AI analysis • Cli
Slide 13: VENTITEST
VENTITEST The SpiroSonic VentiTest is a patent protected digital multi-path ultrasonic ventilator testing and calibration solution which incorporates: Low resistance High resolution bi-directional digital multi- Pressure module to control path acoustic flow piezoresistive monolithic silicon monitor
Slide 14: Global Approvals
Global Approvals 7 New Approvals for FY22 up from 5 (up 140%) Regions Approvals China SE Asia Euro US Russia ROW USCOM ✓ 1A 2021 ✓ ✓ ✓ ✓ ✓ ✓ 2022 China Pending SE Asia ✓ ✓ ✓ ✓ ✓ ✓ Europe US ✓ New Approvals Russia 14 | New Products and New Regions
Slide 15: Global Specialisation
Global Specialisation Transitioning to a complex global organisation requires specialised operational divisions within the company to support efficient growth and expansion Finance and Management Marketing, Sales and Each region accounts and reports Distribution independently and to HQ Global coordi
Slide 16: China Recognition
China Recognition “Building a Global Business” Uscom China Listed as Uscom China ranked China National High AAA Credit Enterprise Technology Enterprise by China Credit by PRC Ministry of Enterprise Publicity Science and Technology Network New Reimbursement for IP Milestones: Two 10yr USCOM 1A examin
Slide 17: Regional Strategy
Regional Strategy Australia China Hungary Singapore UK US Uscom China Expand distribution, prepare BP+ and SpiroSonic marketing and distribution, and develop domestic manufacture Uscom Europe Increase manufacturing capacity to meet demand and increasing distribution and sales for USCOM 1A, BP+ and S
Slide 18: News
News Milestones since 30 June 2021 Russian regulatory approval for USCOM 1A with early sales Two 10yr patents for USCOM 1A in China SpiroSonic AIR passes log 6 High Level Disinfection of Mycobacterium Terrae testing for FDA Local manufacturing in China progressing Technology partnership
Slide 19: Investment
Investment Disconnect = Opportunity UCM Total Cash Receipts UCM Share Price 55 $6.00 $5.58 $5.00 45 $4.60 $4.00 35 $3.64 $3.50 $M AUD $2.94 $2.86 Cents $3.00 25 $2.04 $2.00 15 $1.38 $1.01 $1.00 $0.86 5 $0.00 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2012 2013 2014 2015 2016 2017 2018 20
Slide 20: Founder Led Success
Success Founder led success Alphabet, Amazon, Apple, Facebook, Alibaba, Tencent, Walmart, Samsung, LVMH, Tesla, Oracle, Nike, Seek, Afterpay, WiseTech Global, Goodman Group, TPG Telecom, Xero……. "Using our database of over 1,000 publicly listed family- or founder-owned companies, we calculate an ann
Slide 21: New Growth
New Growth RIGHTS ISSUE Issue - 3:10 Rights Raise - Up to $5.17m Price - $0.11 (17% discount to VWAP) Offer - All Uscom Shareholders USE OF FUNDS Establish China manufacturing – New scale, efficiency and price Expand global distribution - Europe, US, SE Asia and China initiatives Increase clinical s
Slide 22: Summary
Summary FY21 – Performance and Investment “FY21 was a year of investment for Uscom, with continued Strong revenue growth, Operating cash flow positivity, SUMMARY China profit, Europe profit and Multiple device approvals.” FY22 – New Growth “Planned expansion and growth, with new manufacturing to mee
Slide 23: Uscom - New Growth
PRESENTATION AND UPDATE Uscom - New Growth ASX: UCM Prof. Rob Phillips Chairman and CEO, Uscom Limited November 24, 2021
Slide 24: AWC and Uscom - conserving the sugar glider
in the last 15 years Australia's threatened species list has increased by 36%. 87% of our mammal species, 93% of reptiles, 94% of frogs and 45% of our bird species are unique to Australia. AWC is committed to reversing Australia’s record as the world’s mammalian extinction capital. AWC and Uscom - c